Initial studies with SGLT2 inhibitors explored their utility in improving blood sugar control in patients with type II diabetes mellitus (T2DM) by virtue of increased urinary glucose excretion [16,17]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.